HBT Financial, Inc. to Announce Third Quarter 2024 Financial Results on October 21, 2024
BLOOMINGTON, Ill., Oct. 08, 2024 (GLOBE NEWSWIRE) — HBT Financial, Inc. (NASDAQ: HBT) (the “Company” or “HBT Financial”), the holding […]
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and […]
AvidXchange Announces Timing of Its Third Quarter 2024 Financial Results Conference Call and Webcast
CHARLOTTE, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) — AvidXchange Holdings, Inc. (Nasdaq: AVDX), a leading provider of accounts payable (AP) […]
TC Energy announces pricing of cash tender offers
CALGARY, Alberta, Oct. 08, 2024 (GLOBE NEWSWIRE) — News Release – TC Energy Corporation (TSX, NYSE: TRP) (“TC Energy”) today […]
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the […]
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication […]
TSX News -
PrairieSky Royalty Announces Conference Call for Q3 2024 Results
CALGARY, Alberta, Oct. 08, 2024 (GLOBE NEWSWIRE) — PrairieSky will release its Q3 2024 results on Monday, October 28, 2024 […]
Nasdaq Resumes Trading in BAIYU Holdings, Inc.
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading will resume in […]
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) — Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), […]
Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation
The primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including […]
